Medicare's RAPID Path: Faster Gadget Coverage for Gramps
Published Date: 8/11/2026
Notice
Summary
This notice with comment period provides information to the public on the process CMS will use to provide accelerated Medicare coverage through the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway for new innovative technologies. The RAPID coverage pathway leverages existing processes to provide expedited national Medicare coverage for eligible technologies. This notice with comment period solicits public comment on the proposed RAPID coverage pathway.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 2 costs, 1 mixed.
Faster Medicare Coverage for Breakthrough Devices
If a qualifying Breakthrough-designated device meets the pathway rules and FDA gives market authorization, CMS will post a proposed National Coverage Determination (NCD) the same day as FDA authorization. CMS aims to finalize the NCD about 60 days later for Class II devices and about 90 days later for Class III devices, which could speed Medicare beneficiary access to those devices.
Who Can Use the RAPID Pathway
Only certain devices are eligible: presumptive Class II FDA Breakthrough-designated devices in TAP planning a De Novo request, or Class III FDA Breakthrough-designated devices planning a PMA application. The device must be in the IDE presubmission stage and the manufacturer must plan an IDE study that enrolls Medicare beneficiaries and evaluates clinical health outcomes that FDA and CMS agree are appropriate.
Diagnostic Tests (IVDs) Are Excluded
In vitro diagnostic products (IVDs), including diagnostic laboratory tests, will not be accepted into the RAPID coverage pathway in most cases. If an IVD and CMS agree an NCD is appropriate, the manufacturer may instead submit a traditional NCD request following existing procedures.
Higher-Risk Devices May Need More Evidence
Whether CMS requires additional evidence development (Coverage with Evidence Development, CED) will depend on device risk and the strength of IDE study results. Lower-risk devices are more likely to have enough evidence at FDA authorization, while higher-risk devices are more likely to need further evidence and aligned postmarket studies.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14709, Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program; Correction
This correction fixes some typos and technical mistakes in the 2027 health insurance rules under the Affordable Care Act. It mainly affects people and organizations involved in health coverage plans by clarifying when the rules take effect and restoring some important regulation details. These fixes take effect on July 20, 2026, ensuring smoother and clearer health plan operations next year.
2026-12069, Medicare Program; Strengthening Oversight of Accrediting Organizations (AOs) and Preventing AO Conflicts of Interest, and Related Provisions
This new rule makes sure the groups that check Medicare providers play fair and follow clear rules to avoid conflicts of interest. It updates how psychiatric hospitals are reviewed and tightens rules for providers who lost their Medicare status but want back in. These changes affect Medicare providers and accrediting groups, start June 16, 2027, and aim to keep care safe and trustworthy.
2026-10890, Medicare Program; Alternative Payment Model Updates and the Increasing Organ Transplant Access (IOTA) Model
Starting July 1, 2026, Medicare is updating the Increasing Organ Transplant Access (IOTA) Model to help kidney transplant hospitals do even better at getting more people transplanted and improving care quality. These changes affect hospitals involved in kidney transplants and aim to make the process smoother and more effective, with new payment rules that reward success. This update is part of a 6-year plan running through 2031 to save more lives and boost patient experience.
2026-10292, Medicaid Program; Medicaid Managed Care State Directed Payments and Medicaid Fee-for-Service Targeted Medicaid Practitioner Payments
This proposed rule changes how states can pay Medicaid managed care plans and certain doctors to make sure payments are fair, efficient, and encourage enough providers to offer quality care. It affects states, Medicaid managed care organizations, and targeted Medicaid practitioners, aiming to keep payments balanced and services available. Comments on these changes are open until July 21, 2026, so stakeholders have time to weigh in before it’s finalized.
2026-10050, Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program
Starting in 2027, health insurance plans on federal and state marketplaces will see new rules to make coverage fairer and easier to use. These changes affect insurance companies, agents, and people buying plans, including new fees, penalties, and better protections for those with hardships. Expect updates on plan quality, dental coverage limits, and longer-term catastrophic plans, all aiming to keep your health coverage solid and affordable.
2026-07205, Medicare and Medicaid Programs; Patient Protection and Affordable Care Act; Interoperability Standards and Prior Authorization for Drugs for Medicare Advantage Organizations, Medicaid Managed Care Plans, State Medicaid Agencies, Children's Health Insurance Program (CHIP) Agencies and CHIP Managed Care Entities, and Issuers of Qualified Health Plans on the Federally-Facilitated Exchanges
This new rule will help Medicare, Medicaid, CHIP, and health plan companies share patient info more easily and speed up drug approval requests. It affects Medicare Advantage, Medicaid, CHIP, and health plans on federal exchanges, aiming to make care smoother and faster. These changes will start soon and could save time and money by cutting red tape.
Previous / Next Documents
Previous: 2026-16367, Marine Mammals; Incidental Take During Specified Activities; Proposed Incidental Harassment Authorization for Southwest Alaska Stock of Northern Sea Otters in Unalaska, Alaska
We, the U.S. Fish and Wildlife Service (FWS), in response to a request under the Marine Mammal Protection Act of 1972, as amended, from the City of Unalaska, propose to authorize incidental take by harassment of small numbers of Southwest Alaska stock northern sea otters (Enhydra lutris kenyoni) for a period of up to 1 year from the date of issuance. The applicant has requested this authorization for take by harassment that may result from activities associated with pile driving and marine construction at the Robert Storrs Harbor in Unalaska, Alaska. This proposed authorization, if finalized, would be for incidental take by Level A harassment and Level B harassment of northern sea otters from the Southwest Alaska stock. We invite comments on the proposed incidental harassment authorization and the accompanying draft environmental assessment from the public, Tribes, and local, State, and Federal agencies.
Next: 2026-16369, Virginia Electric and Power Company, (Doing Business as Dominion Energy Virginia); North Anna Site; Early Site Permit Renewal Application
The U.S. Nuclear Regulatory Commission (NRC) is providing public notice each week, for four consecutive weeks, of receipt and availability of an application for renewal of early site permit (ESP) ESP-003 for the North Anna ESP site from Virginia Electric and Power Company, doing business as (dba) Dominion Energy Virginia. Renewal of the ESP would allow the licensee to reference ESP-003 in a construction permit (CP) or combined license (COL) application for an additional 20- year period beyond the period specified in the ESP. The location for the North Anna ESP site is in Louisa County, Virginia, and the current ESP-003 expires on November 27, 2027.